Pacer Advisors Inc. Has $4.15 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Pacer Advisors Inc. raised its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 40.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 12,485 shares of the company's stock after purchasing an additional 3,616 shares during the period. Pacer Advisors Inc.'s holdings in Medpace were worth $4,148,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Pallas Capital Advisors LLC increased its position in shares of Medpace by 179.7% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock worth $1,086,000 after purchasing an additional 2,101 shares during the last quarter. Baillie Gifford & Co. increased its position in shares of Medpace by 175.6% in the 3rd quarter. Baillie Gifford & Co. now owns 14,876 shares of the company's stock worth $4,966,000 after purchasing an additional 9,478 shares during the last quarter. Barclays PLC increased its position in shares of Medpace by 71.9% in the 3rd quarter. Barclays PLC now owns 19,781 shares of the company's stock worth $6,603,000 after purchasing an additional 8,275 shares during the last quarter. Oppenheimer Asset Management Inc. increased its position in shares of Medpace by 6.3% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company's stock worth $15,179,000 after purchasing an additional 2,675 shares during the last quarter. Finally, CWA Asset Management Group LLC bought a new stake in shares of Medpace during the 3rd quarter valued at about $1,306,000. Institutional investors own 77.98% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on MEDP. TD Cowen lowered their price objective on shares of Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a research report on Wednesday, October 23rd. Redburn Atlantic began coverage on shares of Medpace in a research report on Monday, October 14th. They set a "buy" rating and a $404.00 price objective for the company. Robert W. Baird boosted their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. William Blair restated an "outperform" rating on shares of Medpace in a research report on Tuesday, October 22nd. Finally, Truist Financial decreased their target price on shares of Medpace from $415.00 to $397.00 and set a "hold" rating for the company in a research report on Monday, October 14th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Medpace presently has an average rating of "Hold" and an average target price of $381.44.

Medpace Stock Performance

Shares of NASDAQ:MEDP traded down $5.77 during trading on Monday, reaching $343.38. The company had a trading volume of 209,369 shares, compared to its average volume of 212,270. The firm's fifty day moving average is $342.50 and its 200 day moving average is $351.36. The firm has a market capitalization of $10.67 billion, a PE ratio of 30.07, a price-to-earnings-growth ratio of 1.79 and a beta of 1.36. Medpace Holdings, Inc. has a twelve month low of $291.15 and a twelve month high of $459.77.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.